Fidelity Management & Research has led a $325m series B round for Biontech, a spinout of Johannes Gutenberg University Mainz whose backers also include Sanofi and Pfizer.

Biontech, a Germany-based immuno-oncology therapy developer spun out of Johannes Gutenberg University Mainz, closed a $325m series B round yesterday led by financial services group Fidelity Management & Research.
Redmile Group, Invus, MiraeAsset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management and the Struengmann Family Office as well as unnamed new and existing investors took part in the round.
Biontech previously obtained $91.5m in equity funding from pharmaceutical firm Sanofi as part of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in